| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/30/2004 | CA2112981C Process for the preparation of optical isomers of a amino-2 napththyridine derivative |
| 03/25/2004 | WO2004024920A1 Preventives/remedies for neurodegenerative diseases |
| 03/25/2004 | WO2004024919A1 Non-sequence complementary antiviral oligonucleotides |
| 03/25/2004 | WO2004024911A1 Enhancers specific to motor nerve cells/sensory nerve cells |
| 03/25/2004 | WO2004024736A1 Antidepressant azaheterocyclylmethyl derivatives of 4,5-dihydroimidazo[1,4,5-de]benzoxazine |
| 03/25/2004 | WO2004024734A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| 03/25/2004 | WO2004024732A1 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 03/25/2004 | WO2004024731A1 Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans |
| 03/25/2004 | WO2004024729A1 Diazabicyclic compounds useful in the treatment of cns and other disorders |
| 03/25/2004 | WO2004024725A1 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants |
| 03/25/2004 | WO2004024723A1 Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan |
| 03/25/2004 | WO2004024719A1 Substituted 1,4-pyrazine derivatives |
| 03/25/2004 | WO2004024714A1 Aroyl-piperidine derivatives |
| 03/25/2004 | WO2004024710A1 Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| 03/25/2004 | WO2004024709A2 Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors |
| 03/25/2004 | WO2004024694A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 03/25/2004 | WO2004024675A1 Substituted aminoethers for the treatment of alzheimer's disease |
| 03/25/2004 | WO2004024673A1 Amino-propanol derivatives |
| 03/25/2004 | WO2004024669A1 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
| 03/25/2004 | WO2004024163A1 Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
| 03/25/2004 | WO2004024155A1 Adhesive patch |
| 03/25/2004 | WO2004024150A2 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression |
| 03/25/2004 | WO2004024136A1 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
| 03/25/2004 | WO2004024134A1 Pharmaceutical formulations of modafinil |
| 03/25/2004 | WO2004024132A2 Use of no-signal cascade modulators and pharmaceutical composition |
| 03/25/2004 | WO2004024130A2 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
| 03/25/2004 | WO2004023870A1 Human slt transgenic animal |
| 03/25/2004 | WO2004014367A3 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease |
| 03/25/2004 | WO2004013138A3 Imidazo`1,2-a!pyridines |
| 03/25/2004 | WO2004013134A3 Compounds |
| 03/25/2004 | WO2004006954A3 Transdermal botulinum toxin compositions |
| 03/25/2004 | WO2004004638A3 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 03/25/2004 | WO2004000849A3 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 03/25/2004 | WO2004000808A3 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/25/2004 | WO2004000289A3 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production |
| 03/25/2004 | WO2003104441A3 Bacterial strain, compositions derived therefrom and methods of using same for treating beta-amyloid peptide-associated deseases |
| 03/25/2004 | WO2003104207A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/25/2004 | WO2003103603A3 Novel formate salt of o-desmethyl-venlafaxine |
| 03/25/2004 | WO2003094842A3 Conjugates comprising central nervous system active drug |
| 03/25/2004 | WO2003093485A3 Optimization of transgene expression in mammalian cells |
| 03/25/2004 | WO2003092624A3 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 03/25/2004 | WO2003090726A3 Chewable soft capsule |
| 03/25/2004 | WO2003086326A3 G-type peptides to ameliorate atherosclerosis |
| 03/25/2004 | WO2003086306B1 5ht2c receptor modulators |
| 03/25/2004 | WO2003084941A3 Hydroxamic acid derivatives |
| 03/25/2004 | WO2003077949A3 Methods of treating diabetes using pde 11a inhibitors |
| 03/25/2004 | WO2003077869A3 Neuroprotective spirostenol pharmaceutical compositions |
| 03/25/2004 | WO2003072528A3 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 03/25/2004 | WO2003059372A3 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 03/25/2004 | WO2003057721A3 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 03/25/2004 | WO2003047558A3 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| 03/25/2004 | WO2003043613A3 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 03/25/2004 | WO2003040134A9 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 03/25/2004 | WO2003037361A3 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| 03/25/2004 | WO2003033680A3 Kinases and phosphatases |
| 03/25/2004 | WO2003020749A3 Ncam binding compounds |
| 03/25/2004 | WO2003016351A3 N - cam related compounds modulating cell groth |
| 03/25/2004 | WO2003015812A3 Beta-amyloid-analogue-t-cell epitop vaccine |
| 03/25/2004 | WO2003015612A3 Materials and methods to promote repair of nerve tissue |
| 03/25/2004 | WO2003014731B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 03/25/2004 | WO2003014121A9 Compounds, derivatives, compositions, preparation and uses |
| 03/25/2004 | WO2003004480A3 Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| 03/25/2004 | WO2002089797A8 Treatment of adhd |
| 03/25/2004 | WO2002072832A3 Therapeutic binding molecules |
| 03/25/2004 | WO2002063006A3 Receptors and membrane-associated proteins |
| 03/25/2004 | WO2002051433A3 Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament |
| 03/25/2004 | WO2002044342A3 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| 03/25/2004 | WO2002039998A3 Methods and compositions for regulating memory consolidation |
| 03/25/2004 | US20040060077 Using dietary restriction to lower serum insulin levels and function as tool in treatment and prevention of alzheimer's diseases |
| 03/25/2004 | US20040059241 Method for classifying and treating physiologic brain imbalances using quantitative EGG |
| 03/25/2004 | US20040059132 Reacting an indolin-2-one derivative with substituted benzyl halide to form substituted N-benzyl indolin-2-one derivatives have an affinity for oxytocin receptors |
| 03/25/2004 | US20040059113 Such as 3-(1-(2-hydroxyethyl)-1H-indol-3-yl)-4-(1-(3-pyridinyl)-1H-indol-3-yl)-1H -pyrrole-2,5-dione |
| 03/25/2004 | US20040059110 Such as N,N'-bis(2-hydroxybenzyl)-L-cystine |
| 03/25/2004 | US20040059109 Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics |
| 03/25/2004 | US20040059107 Which has superoxide acitivity, catalase activity, and/or peroxidase activity; for treating cell or tissue damage; pharmaceutical formulations, improved cell and organ culture media, cryopreservation media, antiaging, chemoprotective and radioprotective uses |
| 03/25/2004 | US20040059004 10-aryl-11h-benzo[b]fluorene derivatives and analogs for medicinal use |
| 03/25/2004 | US20040058994 Local prevention or amelioration of pain from surgically closed wounds |
| 03/25/2004 | US20040058991 Anticonvulsants; central nervous system disorders |
| 03/25/2004 | US20040058989 Solid dosage form; antidepressant |
| 03/25/2004 | US20040058987 Hypotensive agents; oxidation resistance, nitrogen scavenger; anticancer agents; antiischemic agents |
| 03/25/2004 | US20040058986 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 03/25/2004 | US20040058980 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 03/25/2004 | US20040058966 Method for reducing or eliminating smoking |
| 03/25/2004 | US20040058964 Antiinflammatory agents; antiarthritic agents; antihistamines; sepsis shock; antidiabetic agents; bone disorders |
| 03/25/2004 | US20040058953 Antidepressants; obsessive-complusive disorders; eating disorders; sleep disorders; dietetics; drug abuse |
| 03/25/2004 | US20040058947 Composition for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder |
| 03/25/2004 | US20040058945 N-type calcium channel antagonists for the treatment of pain |
| 03/25/2004 | US20040058941 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 03/25/2004 | US20040058935 Crystals; storage stability; psychological disorders |
| 03/25/2004 | US20040058933 Aryl carbamate derivatives, preperation and use thereof |
| 03/25/2004 | US20040058932 Novel piperazine derivatives |
| 03/25/2004 | US20040058927 Tackykinin antagonist |
| 03/25/2004 | US20040058925 Method of treating fibromyalgia and other somatoform disorders |
| 03/25/2004 | US20040058923 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 03/25/2004 | US20040058922 Tyrosine inhibitor; immunosuppressants; antiarthritic agents; autoimmune diseases; antiproliferative agent |
| 03/25/2004 | US20040058921 Psychological disorders; antidepressants; sexual disorders ; eating disorders |
| 03/25/2004 | US20040058920 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 03/25/2004 | US20040058916 Central nervous system disorders; psychological disorders; schizophrenia; antiarthritic agents; Alzheimer's disease; anticancer agents |
| 03/25/2004 | US20040058914 Combination drugs |
| 03/25/2004 | US20040058912 Psychological disorders; eating disorders; dietetics |